S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
pixel
Log in
NASDAQ:QLI

Qilian International Holding Group Stock Forecast, Price & News

$8.34
-0.19 (-2.23 %)
(As of 01/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.88
Now: $8.34
$8.54
50-Day Range N/A
52-Week Range
$7.52
Now: $8.34
$22.00
Volume591,627 shs
Average Volume3.60 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Qilian International Holding Group Limited engages in the research, development, and production of active pharmaceutical ingredients (APIs) and traditional Chinese medicine derivative (TCMD) products in China. The company offers licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It also provides Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings comprising Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to enhance crop yield and soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to enhance plant growth. The company was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

MarketRank

Overall MarketRank

0.00 out of 5 stars

Medical Sector

1890th out of 1,926 stocks

Drug Manufacturers—Specialty & Generic Industry

46th out of 51 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Drug Manufacturers—Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:QLI
CUSIPN/A
CIKN/A
WebN/A
Phone86 93 7268 9523
Employees279

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable
$8.34
-0.19 (-2.23 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive QLI News and Ratings via Email

Sign-up to receive the latest news and ratings for QLI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Qilian International Holding Group (NASDAQ:QLI) Frequently Asked Questions

What stocks does MarketBeat like better than Qilian International Holding Group?

Wall Street analysts have given Qilian International Holding Group a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Qilian International Holding Group wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Qilian International Holding Group's CEO?

1,448 employees have rated Qilian International Holding Group CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Qilian International Holding Group's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Qilian International Holding Group's key competitors?

Who are Qilian International Holding Group's key executives?

Qilian International Holding Group's management team includes the following people:
  • Mr. Zhanchang Xin, Chairman of Directors, CEO & Acting Principal Financial Officer

When did Qilian International Holding Group IPO?

(QLI) raised $30 million in an initial public offering (IPO) on Tuesday, January 12th 2021. The company issued 5,000,000 shares at $5.00-$7.00 per share. Univest Securities served as the underwriter for the IPO and Loop Capital Markets was co-manager.

What is Qilian International Holding Group's stock symbol?

Qilian International Holding Group trades on the NASDAQ under the ticker symbol "QLI."

When does Qilian International Holding Group's quiet period expire?

Qilian International Holding Group's quiet period expires on Monday, February 22nd. Qilian International Holding Group had issued 5,000,000 shares in its public offering on January 12th. The total size of the offering was $25,000,000 based on an initial share price of $5.00. During Qilian International Holding Group's quiet period, underwriters and any insiders that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Qilian International Holding Group?

Shares of QLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Qilian International Holding Group's stock price today?

One share of QLI stock can currently be purchased for approximately $8.34.

How can I contact Qilian International Holding Group?

The company can be reached via phone at 86 93 7268 9523.

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.